Re: ZEN-3694 Single Agent Trial Status
in response to
by
posted on
Jan 16, 2018 09:22AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
narmac - Liquidity is definitely an issue however not impossible if the shares are in a cash account or non registered account. I have heard of a number transactions that have occurred with Zenith shares between .10 and .65. There is some liquidity just not much. In these cases that I have heard about it was the buyer that had the upper hand. This lack of liquidity may also force some that would otherwise deal their future away into hanging onto to those shares and collect a future royalty despite themselves. Wouldn't that be a nice gift if it actually happens. My fingers are crossed. We should have a better idea what to expect before the end of this year and frankly it wouldn't surprise me to get a good indication within the next 6 months. The lack of control of ones own destiny is frustrating without question.
tada